Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Hummingbird Bioscience announced that HMBD-001, an anti-HER3 monoclonal antibody developed using its AI Molecular Medicine platform, has advanced into Phase II clinical trials for advanced squamous cell cancers in combination with cetuximab. The first patient has been dosed in the HMBD-001-103 study, with recommended doses identified based on safety, tolerability, and preliminary efficacy data. The advancement demonstrates the company's AI-first approach to drug discovery and development.